Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck

Parthan, Anju; Posner, Marshall R.; Brammer, Caroline; Beltran, Philippe; Jansen, Jeroen P.

doi:10.1002/hed.21096

Cited by 26 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these studies were deemed inappropriate for the derivation of the current model recurrence health states because the majority either reported only utilities derived from the EORTC QLC-C30 questionnaire (a cancer-specific health-related quality-of-life questionnaire), which cannot be easily converted in to EQ-5D utilities, [78][79][80][81] or did not report health state utilities that could be reliably mapped to the health states used in the current model. 82 One UK study 83 was identified. However, this study calculated EQ-5D utilities from a sample of 50 oncology nurses; because health-care professionals are known to be poor proxies for patients, this study was similarly excluded from consideration for the base-case analysis.…”

Section: Model Parametersmentioning

confidence: 99%

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer

Mehanna

McConkey

Rahman

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomographycomputerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 2017;21(17). This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment is indexed and abstracted inEditorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 06/302/129. The contractual start date was in April 2007. The draft report began editorial review in July 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily ref...

show abstract

Section: Model Parametersmentioning

confidence: 99%

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer

Mehanna

McConkey

Rahman

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Therefore, investigators have started to add these agents in induction chemotherapy regimens. Several phase II and III trials have indicated that taxanes plus cisplatin and fluorouracil (TPF) might be more efficacious and cost-effective than the PF regimen [17], [18], [19], [20], [24], [25]. However, in 2009, Pointreau et al [13] reported another phase III study that demonstrated no significant difference in the 3-year overall survival between regimens (60% in each arm), and the disease-free interval in patients suffering laryngeal or hypopharyngeal cancer.…”

Section: Discussionmentioning

confidence: 99%

Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis

et al. 2012

View full text Add to dashboard Cite

BackgroundSome investigations have suggested that induction chemotherapy with a combination of taxanes, cisplatin and fluorouracil (TPF) is effective in locally advanced head and neck cancer. However, other trials have indicated that TPF does not improve outcomes. The objective of this study was to compare the efficacy and safety of TPF with a cisplatin and fluorouracil (PF) regimen through a meta-analysis.MethodsFour randomized clinical trials were identified, which included 1,552 patients with locally advanced head and neck cancer who underwent induction chemotherapy with either a TPF or PF protocol. The outcomes included the 3-year survival rate, overall response rate and different types of adverse events. Risk ratios (RRs) and their 95% confidence intervals (CIs) were pooled using RevMan 5.1 software.ResultsThe 3-year survival rate (51.0% vs. 42.4%; p = 0.002), 3-year progression-free survival rate (35.9% vs. 27.2%; p = 0.007) and overall response to chemotherapy (72.9% vs. 62.1%; p<0.00001) of the patients in the TPF group was statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia (7.0% vs. 3.2%; p = 0.001) and alopecia (10.8% vs. 1.1%; p<0.00001) was higher in the TPF group.ConclusionThe TPF induction chemotherapy regimen leads to a significant survival advantage with acceptable toxicity rates for patients with locally advanced head and neck cancer compared with the PF regimen.

show abstract

“…Posner et al [151] (TAX324) showed, in 501 patients with locally advanced HNSCC, that induction therapy with a TPF triple combination (docetaxel, cisplatin and 5-FU), compared with the “tried and tested” treatment regimen consisting of a combination of cisplatin and 5-FU (PF), produced a more than two-fold increase in median survival time (70.6 vs. 30.1 months) in a relatively cost-effective manner [143]. This was equivalent to a 30% relative reduction in the risk of death.…”

Section: Cytostaticsmentioning

confidence: 99%

Systemic therapy strategies for head-neck carcinomas: Current status

Hoffmann¹

2012

GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery; 11:Doc03; ISSN 1865-1011

View full text Add to dashboard Cite

Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck

Abstract: TPF is cost-effective as induction chemotherapy in locally advanced SCCHN compared with PF. Local treatment patterns may impact findings for other countries.

Cited by 26 publications

References 11 publications

Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis

Systemic therapy strategies for head-neck carcinomas: Current status

Contact Info

Product

Resources

About